31 March 2022

SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2022

Sparingvision - Ysios Capital

Paris, March 31, 2022 – SparingVision (“the Company”), a genomic medicine company developing vision saving treatments for ocular diseases, announces today that it will be presenting data on its lead product candidate SPVN06 and the natural history of retinitis pigmentosa, its core focus indication, at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting to be held from 1-4 May.

SparingVision have been selected for an oral presentation and for two poster presentations.

Details can be found below:

Oral Presentation: Prospective natural history of retinitis pigmentosa due to RHO, PDE6A, or PDE6B mutations: interim analysis of the PHENOROD2 study

Date and Time: May 4, 2022 from 3:51 PM to 4:08 PM MDT, Presentation #4294

Presenter: Anne Celle

Session Title: Retinal Degeneration

Room: 205/207 (Denver Convention Center)

Poster Presentation: Retrospective natural history of retinitis pigmentosa due to RHO, PDE6A, or PDE6B mutations: the PHENOROD1 study
Date and Time: May 4, 2022 from 3:00 PM to 5:00 PM MDT, Poster #4497 – F0284

Presenter: Alice Le Meur

Session Title: Retinal Degenerations, Gene Therapy, Transplantation, and Prostheses

Poster Presentation: SPVN06, a novel mutation-independent AAV-based gene therapy, dramatically reduces vision loss in the rd10 mouse model of rod-cone dystrophy

Date and Time: May 1, 2022 from 12:15 PM to 2:15 PM MDT, Poster #56 – A0029

Presenter: Dr. Florence Lorget, PharmD, PhD, DABT

Session Title: Gene Therapy and Gene Editing for Ocular Disorders

About SparingVision

SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments. Leveraging its unparalleled understanding of retinal diseases, SparingVision has built the world’s most compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for inherited retinal diseases (IRDs). Both of its most advanced products, SPVN06 and SPVN20 look to go beyond single gene correction therapies to deliver new mutation agnostic treatments for Retinitis Pigmentosa (RP), a group of IRDs which are the leading cause of blindness globally. The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ:NTLA) to develop novel genome editing-based treatments for ocular diseases utilizing CRISPR-Cas9 technology.

SparingVision is backed by high-quality international investors including 4BIO Capital, AdBio Partners, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, Intellia Therapeutics, UPMC Enterprises, Jeito Capital, Ysios Capital.

Visit www.sparingvision.com for more and follow us on LinkedIn and Twitter @SparingVision.

About SPVN06:

SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy approach comprised of one neurotrophic factor and one enzyme reducing oxidative stress which, acting synergistically, aim at slowing or stopping the degeneration of cone photoreceptors, which inevitably leads to blindness in patients with rod-cone dystrophies (RCD). SparingVision’s primary disease target is Retinitis Pigmentosa (RP), one of the most common inherited retinal diseases that affects two million patients worldwide. There is currently no treatment approved to treat RP patients independently of their genetic background. This approach is potentially applicable to many more diseases where the loss of rods is known to be an early signal of the disease. First-in-man trials, with SPVN06 in patients with RP, will be commencing in H2 2021.


Stéphane Boissel, President and CEO
Nathalie Trepo, Investor Relations

Consilium Strategic Communications
Amber Fennell, Genevieve Wilson, Davide Salvi
+44 (0)20 3709 5700